ANGO · XBRL financial data

AngioDynamics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANGO's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Revenue	291,010	—	—	—	—	—
Revenue from contracts with customers	291,010	316,219	338,752	303,914	292,498	320,174
Cost of goods and services sold	134,222	150,487	164,506	149,216	134,793	145,282
Gross profit	156,788	165,732	174,246	154,698	157,705	174,892
Research and development	36,390	30,739	29,883	31,512	26,222	29,447
General and administrative	35,918	38,451	40,003	41,164	42,092	43,691
Total operating expenses	192,071	194,203	225,427	401,632	197,659	214,819
Operating income (loss)	(35,283)	(28,471)	(51,181)	(192,435)	(39,954)	(39,927)
Interest expense	861	688	2,702	(1,614)	—	—
Other income (expense)	92	(790)	(554)	(817)	4,944	3,926
Income tax expense (benefit)	(4,504)	(3,402)	(1,995)	(7,289)	(39)	442
Net income (loss)	(31,548)	(26,547)	(52,442)	(184,349)	(33,993)	(36,742)
Earnings per share, basic USD per share	(0.82)	(0.68)	(1.33)	(4.59)	(0.83)	(0.88)
Earnings per share, diluted USD per share	(0.82)	(0.68)	(1.33)	(4.59)	(0.83)	(0.88)
Weighted average shares, basic thousands of shares	38,342	39,009	39,480	40,181	40,853	41,526
Weighted average shares, diluted thousands of shares	38,342	39,009	39,480	40,181	40,853	41,526

Fiscal years (ANGO's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Cash and cash equivalents	48,161	28,825	44,620	76,056	55,893	53,864
Accounts receivable	35,405	52,304	52,826	43,610	42,890	48,325
Inventory	48,614	51,392	55,325	60,616	62,006	52,436
Prepaid and other current assets	8,699	10,824	4,617	12,971	7,535	8,769
Total current assets	140,879	143,345	163,542	193,253	168,324	163,394
Property and equipment, net	37,073	45,005	44,384	35,666	32,300	27,097
Right-of-use asset	9,382	6,974	5,113	5,804	3,850	5,053
Goodwill	201,316	201,058	159,238	0	—	—
Total assets	561,438	552,751	532,637	317,671	280,144	267,163
Accounts payable	19,630	28,047	40,445	37,751	33,291	31,513
Accrued liabilities	35,459	34,842	26,617	41,098	35,518	38,909
Total current liabilities	57,584	74,324	83,825	91,155	76,197	74,717
Lease liability, non-current	7,319	4,703	3,316	3,939	2,106	3,860
Total liabilities	121,981	128,262	154,341	112,085	97,174	96,338
Accumulated deficit	(131,866)	(158,413)	(210,855)	(395,204)	(429,197)	(465,939)
Total stockholders' equity	439,457	424,489	378,296	205,586	182,970	170,825
Total liabilities and equity	561,438	552,751	532,637	317,671	280,144	267,163
Common shares outstanding (cover page) thousands of shares	38,444	38,970	39,671	40,277	40,634	41,332

Fiscal years (ANGO's year ends in late May)

In thousands of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Net income (loss)	(31,548)	(26,547)	(52,442)	(184,349)	(33,993)	(36,742)
Stock-based compensation	8,625	10,692	11,158	10,529	9,772	13,960
Net cash from operating activities	24,093	(7,194)	78	(28,158)	(10,128)	3,089
Purchases of property and equipment	5,187	4,297	3,812	2,518	4,464	2,581
Net cash from investing activities	(13,711)	(19,307)	(9,746)	123,717	(10,178)	(5,949)
Share repurchases	—	—	0	0	1,670	0
Repayments of long-term debt	20,000	0	45,000	50,000	0	0
Net cash from financing activities	(16,986)	7,683	25,420	(64,248)	(255)	564
Net change in cash	(6,274)	(19,336)	15,795	31,436	(20,163)	(2,029)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.